Bezitramide (INN, USAN, trade name Tramal) is an opioid analgesic drug of the benzomorphan class, which is related to the phenylpiperidine class of opioids such as fentanyl and alfentanil. It was developed by Janssen Pharmaceutica, and is used as an analgesic for moderate to severe pain. Bezitramide is available in both immediate-release and slow-release forms, and is used for the management of acute and chronic pain. Its effects are similar to those of other opioids, such as morphine and codeine, but it has a longer duration of action. Bezitramide is also used as a sedative, muscle relaxant and anesthetic.
Bezitramide was an opioid analgesic, a type of medication used to relieve pain, that was withdrawn from the market due to safety concerns. It was discovered in 1961 and marketed under the trade name Burgodin. Bezitramide itself is a prodrug, meaning it needs to be broken down by the body to become active. Once Bezitramide is broken down, it turns into despropionyl-bezitramide, which is the active metabolite.
Bezitramide was withdrawn from the market in 2004 after several cases of fatal overdose, including one involving a child. It is no longer available for medical use and is considered a Schedule II controlled substance in the United States, meaning it has a high potential for abuse and dependence.
Here are some additional details about Bezitramide:
- Chemical formula: C31H32N4O2
- Molar mass: 492.61 g/mol
- Route of administration: Oral
- Mechanism of action: Opioid agonist
It is important to note that Bezitramide is not a safe or effective medication and should not be used. If you are considering using Bezitramide, it is important to speak to a healthcare professional about the risks and benefits of other treatment options.